


CLINICAL AND ECONOMIC BURDEN OF OSTEOPOROSIS ON THE US HEALTHCARE SYSTEM

Understand and address the impact of osteoporosis and fracture risk



EXPERTS ACKNOWLEDGE THERE IS A CRISIS IN OSTEOPOROSIS MANAGEMENT¹

Postmenopausal osteoporosis diagnosis rates have been declining since 2009, even as a decline in hip fractures has plateaued^{2,*}




Rates of testing and diagnosis are declining and may be **increasing plans'** exposure to the high cost of fractures^{1,2}

The increase in fracture-related expenses is likely to outweigh the modest savings to Medicare from decreased DXA reimbursement and fewer DXAs performed²

OSTEOPOROSIS-RELATED FRACTURE RATES ARE ON THE RISE³

More recent data shows an increase in fracture rates³



Total fracture rates increased beginning in 2016 across various fracture sites including spine, hip, and radius/ulna, among other fracture sites

Increased age- and sex-adjusted
US fracture rates supports the global call
to action to increase screening and
treatment of osteoporosis in older adults



THERE IS A HIGH PREVALENCE OF OSTEOPOROSIS AND OSTEOPOROSIS-RELATED FRACTURES IN THE UNITED STATES⁴



Approximately **10 million Americans** are affected by osteoporosis⁵



Someone in the US breaks their hip every 2 minutes^{6,*}



Every year, there are **1.5 million**osteoporosis-related fractures
in the United States^{4,7}





1 in 2 women and 1 in 4 men over the age of 50 will experience a fracture related to osteoporosis in their remaining lifetime^{4,8}




THERE IS AN URGENT NEED TO ADOPT A PROACTIVE APPROACH TO REDUCING FRACTURES⁹


The incidence of fractures is increasing:





But treatment for the disease is not:






BMD=bone mineral density; MAPD=Medicare Advantage prescription drug.




^{*}Estimate based on a microsimulation forecasting model utilizing risk assessment tool, NHANES, data from published literature, and the US Census Bureau.¹⁰
†Study period July 1, 2010, through June 30, 2014, and included women 67-85 years of age who experienced one or more fractures and received a prescription for an antiosteoporosis medication with or without a BMD test. Patients had continuous Humana MAPD enrollment 12 months prior to and 6 months after the fracture.¹¹

OSTEOPOROSIS-RELATED FRACTURES CAN IMPACT YOUR SYSTEM AS MUCH AS MYOCARDIAL INFARCTIONS¹²







However, treatment rates after hospitalization for hip fracture are declining^{14,††}

INITIAL FRACTURES INCREASE THE RISK OF MORE COSTLY SUBSEQUENT FRACTURES¹⁵

Among those experiencing an initial fracture, the statistics are not promising:



increased risk of a subsequent fracture in patients who have experienced an initial fracture¹⁶



greater chance that postmenopausal women will suffer another fracture within the first year of an osteoporosis-related fracture, and the risk remains elevated over time¹⁷



greater medical cost

for those who experienced a second fracture compared to those who experienced one fracture¹⁸



incremental direct medical

costs during the 180-day period after a subsequent osteoporosis-related fracture^{15,‡‡}

BMD=bone mineral density; HMO=health maintenance organization; MI=myocardial infarction; PPO=preferred provider organization.

- *Based on the total population cost for hospitalization per year for the 2000-2011 time period in women ≥55 years of age. 12
- †Hospitalization rate during 2000-2011 in women ≥55 years of age.12
- [‡]Based on the 6-month follow-up period for women aged 67-85 years who had an osteoporosis-related fracture and received a BMD test and/or an osteoporosis-specific medication, with or without a BMD test.¹¹
- §Statin therapy for patients with cardiovascular disease who received and adhered to statin therapy: Medicare HMO=77.3% and Medicare PPO=76.8%.13
- **Statin Therapy for Patients With Cardiovascular Disease assesses males 21-75 years of age and females 40-75 years of age who have clinical atherosclerotic
- cardiovascular disease (ASCVD) and who received and adhered to statin therapy.¹³
- ††Study includes both male and female patients.14
- #Adjusted for differences in risk characteristics between populations of Medicare FFS beneficiaries with a new osteoporosis-related fracture who had a subsequent fracture and those who did not.¹⁵



PATIENTS WITH OSTEOPOROSIS-RELATED FRACTURES HAD HIGHER MEAN ALL-CAUSE HEALTHCARE COSTS ACROSS ALL 5 YEARS AFTER FRACTURE¹⁹

Amgen studied the impact of all-cause healthcare costs in select Medicare and commercial populations*



The direct economic burden associated with fractures remains high **over the 5 years** after index fragility

fracture[†]

The cost of a fragility fracture is **higher in the first year** compared with the fracture-free patient group
and **remains high in years 2 through 5**

 Incremental direct costs in year 1 for all fracture types range between \$17K and \$75K for commercial patients and between \$23K and \$49K for Medicare patients

Direct Cost Assessment



Compared with fracture-free patients, hip, vertebral, and nonhip nonvertebral fracture patients had higher adjusted all-cause healthcare costs across all 5 years postindex periods in both commercially enrolled and Medicare Advantage patients



While the cost difference decreased from year 1 to year 5 postindex periods but remained significant, the costs between 2 years and 5 years postindex was largely consistent and significant versus the fracture-free patient group

*The study compared direct healthcare costs between female fracture patients (both commercially enrolled patients and Medicare supplemental patients) and demographically matched fracture-free patients for the 5 years after index fracture, by site of fracture using claims from the IBM MarketScan® Commercial Claims and Encounters Database (Commercial) and MarketScan® Medicare Supplemental and Coordination of Benefits Database (Medicare). The assessment included all-cause healthcare costs, which include total payment by both patient and payer on direct costs from: inpatient admissions, ER visits, outpatient services and visits (such as outpatient office visits, skilled nursing facility [SNF] services, and other outpatient services), and outpatient pharmacy claims. Inclusion criteria included one or more nondiagnostic medical claims with a closed or pathological fracture diagnosis in any position between 1/1/2008 through 12/31/2016.

†Index fracture refers to the initial osteoporosis-related fracture during the study design period.



MANY PATIENTS WHO EXPERIENCE AN OSTEOPOROSIS-RELATED FRACTURE DO NOT RECEIVE OPTIMAL CARE²⁰

Currently, the care for many patients who have experienced an osteoporosis-related fracture can be fragmented and ineffective^{4,20}

Quality is an element of a post-fracture care (PFC) program^{21,22}

- Institutionalize PFC quality improvement as part of the organizational culture^{21,22}
- Develop a method to **track administrative data** and identify patients who have had a fracture¹¹
- Establish a baseline for post-fracture patients from which an **improvement of PFC**service can be assessed²²
 - The program provides a centralized source and tools for management of the population at risk for subsequent fractures through patient-centered care and improved communication pathways²²
 - Compare your current program to the HEDIS quality measure. This measure has been used to assess the quality of care in women with osteoporosis²³

A post-fracture care program, such as an FLS, is a systematic approach that can help address gaps in osteoporosis care^{20,22}



THE QUADRUPLE AIM GUIDES HEALTHCARE ORGANIZATIONS TO OPTIMIZE HEALTH SYSTEM PERFORMANCE AND MEET THEIR POPULATION HEALTH GOALS²⁴




A formalized post-fracture care program, such as a fracture liaison service, may be associated with post-fracture treatment rates higher than typical rates^{25,26}



HELP PATIENTS AT RISK FOR OSTEOPOROSIS-RELATED FRACTURES RECEIVE EVALUATION AND PROPER DIAGNOSIS

Improving patient outcomes begins with the three "I"s^{4,7}



Consider implementing a post-fracture care program to proactively screen, evaluate, and treat appropriate patients with PMO who are at risk for fractures²¹



SUMMARY



Rates of testing and diagnosis may be declining and increasing plans' exposure to the high cost of fractures^{1,2}



Osteoporosis-related fracture rates **began increasing** between 2016 and 2017³



Initial fractures increase the risk of costly subsequent fractures¹⁵



A formalized post-fracture care program is one way to help meet population health goals for patients with osteoporosis at high risk for fractures²⁷

Ensure patients at risk for osteoporosis-related fractures receive evaluation and proper diagnosis. Appropriate treatment can help reduce the risk of osteoporosis-related fractures^{1,3,15}



AMGEN AND UCB CAN PROVIDE EDUCATIONAL RESOURCES TO SUPPORT POST-FRACTURE CARE. CONTACT YOUR ACCOUNT MANAGER FOR MORE RESOURCES

References: 1. The American Society for Bone Mineral Research. Call to action to address the crisis in the treatment of osteoporosis. https://www.asbmr.org/Assets/d5139738-e1b3-4645-859a-96affc059ae3/636098972158530000/call-to-action-to-address-the-crisis-in-the-treatment-of-osteoporosis-final-003-pdf. Accessed February 22, 2021. 2. Lewiecki EM, Adler R, Curtis J, et al. Hip fractures and declining DXA testing: at a breaking point? Poster presented at: Annual Meeting of the American Society for Bone and Mineral Research; September 16-19, 2016; Atlanta, GA. 3. Lewiecki EM, Chastek B, Sundquist K, et al. Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. Osteoporos Int. 2020;31:1299-1304. 4. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004. 5. National Osteoporosis Foundation. Osteoporosis fast facts. https://cdn.nof.org/wp-content/uploads/2015/12/ Osteoporosis-Fast-Facts.pdf. Accessed February 22, 2021. 6. Agency for Healthcare Research and Quality. HCUPnet - hospital inpatient national statistics. https://hcupnet.ahrq. qov/#querv/eyJBTkFMWVNJU19UWVBFljpblk-FUX1EiXSwiWUVBUIMi0IsiWVJfMjAx%20NCJdLCJDQVRFR09SSVpBVEIPTI9UWVBFljpblkNUX0NDU0QiXSwiUVVJ%20Q0tUQ%20UJMR-V9UWVBFljpbllFUVF9ERVQiXSwiREFUQVNFVF9TT1VSQ0UiOlsiRFNfTklTll19. Accessed February 22, 2021. 7. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381. 8. National Osteoporosis Foundation. Just for men. https://www.nof.org/preventing-fractures/general-facts/just-formen/. Accessed February 22, 2021. 9. Walters S, Khan T, Ong T, Sahota O. Fracture liaison services: improving outcomes for patients with osteoporosis. Clin Interv Aging. 2017;12:117-127. 10. Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 2019;3:e10192. 11. Boytsov NN, Crawford AG, Hazel-Fernandez LA, et al. Patient and provider characteristics associated with optimal post-fracture osteoporosis management. Am J Med Qual. 2017;32:644-654. 12. Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90:53-62. 13. National Committee for Quality Assurance. Statin therapy for patients with cardiovascular disease and diabetes (SPC/ SPD). https://www.ncga.org/hedis/measures/statin-therapy-for-patients-with-cardiovascular-disease-and-diabetes/. Accessed February 22, 2021. 14. Desai RJ, Mahesri M, Abdia Y, et al. Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures. JAMA Network Open. 2018;1(3):e180826. 15. Hansen D, Bazell C, Pelizzari P, Pyenson B. Milliman Research Report. Medicare cost of osteoporotic fractures. http://assets.milliman.com/ektron/Medicare_cost_of_osteoporotic_fractures.pdf. Accessed February 22, 2021. 16. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375-382. 17. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102. 18. Song X, Shi N, Badamgarav E, et al. Cost burden of second fracture in the US health system. Bone. 2011;48:828-836. 19. Data on file, Amgen; 2020. 20. Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012 27:2039-2046. 21. Curtis J, Silverman SL. Commentary: The five Ws of a fracture liaison service: why, who, what, where and how? In osteoporosis, we reap what we sow. Curr Osteoporos Rep. 2013;11:365-8. 22. Miller AN, Lake AF, Emory CL. Establishing a fracture liaison service: an orthopaedic approach. J Bone Joint Surg Am. 2015:97:675-681. 23. National Committee for Quality Assurance. Osteoporosis testing and management in older women (0T0, 0MW). https://www.ncqa.org/hedis/measures/osteoporosis-testing-and-management-in-older-women/. Accessed February 22, 2021. 24. Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med. 2014;12:573-576. 25. Capture the Fracture. What is a post fracture care coordination program (PFC)? https://www.capturethefracture.org/what-is-a-pfc. Accessed February 22, 2021. 26. Newman ED. Perspectives on pre-fracture intervention strategies: the Geisinger Health System Osteoporosis Program. Osteoporos Int. 2011;22:S451-S455. 27. Solomon DH, Patrick AR, Schousboe J, Losina E. The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. J Bone Miner Res. 2014 29:1667-1674.

